Pick a semester and a book — read its full first chapter free, no account needed.
Chapter 1: Introduction to Pharmaceutical Microbiology
By Nandhakumaran Subramanian, Selvakumar Muruganantham
Pharmaceutical microbiology lies at the heart of medicine and drug development, and has a unique paradox in that microorganisms are essential biological factories and potential contaminants. The chapter covers, in detail, the principles of pharmaceutical microbiology, starting from the basics, which include the history of microbial events that have shaped the discipline from Pasteur's germ theory to Fleming's discovery of penicillin. The chapter systematically reviews the various groups of microorganisms relevant to pharmacy: bacteria, fungi and viruses, their structure and pharmaceutical importance. It also elaborates on the methods of microbial cultivation, classification of culture media, and also on the methods of isolation, like streak plate, spread plate, and pour plate methods. The most commonly used microbial enumeration methods, such as viable counting, membrane filtration, MPN and newer methods like ATP bioluminescence and MALDI-TOF mass spectrometry, are explained in detail. The dual nature of microorganisms as producers of life-saving antibiotics, biopharmaceuticals, and vaccines, and as important contaminants that need careful quality control, is explored in great depth. In this chapter, the basic knowledge of microbiology for pharmaceutical sciences is laid down.
Pharmaceutical microbiology is one of the most essential branches of pharmacy that is plagued by a fundamental paradox; microorganisms are the most valuable biological factories of the industry, and at the same time, the most dangerous contaminant in the industry. As beneficial organisms, microbes are used to create useful life-saving products like recombinant proteins, enzymes, vitamins, vaccines and antibiotics by chemical transformations and fermentation. On the other hand, their presence is dangerous because they are contaminants of the product; sterile products such as infusion, eye drops, etc., must be sterile, meaning free from pathogens and pyrogens, which is why their presence is dangerous.
Microbiology has greatly contributed to the evolution of contemporary medicine and pharmaceutical sciences. Microorganisms, which have long been regarded as disease agents, are now known to be useful in the manufacture of antibiotics, vaccines, enzymes, hormones and other therapeutic products. The association between microbes and medicines started when it was realised that microbes cause disease, and was extended to the use of microbes for useful medical purposes.
This transformation paved the way for the modern pharmaceutical industry and started the biotechnology and biopharmaceuticals era. The dual role of microorganisms in beneficial applications to quality assurance is illustrated in Figure 1.1
Microorganisms and medicine are closely intertwined as part of the Germ Theory of Disease , which posits that certain microorganisms generate certain diseases. This theory was not accepted until before them, diseases were blamed on supernatural causes or on the imbalance of body fluids. The germ theory transformed medicine by giving scientists a scientific explanation for infectious diseases and stimulated the use of sterilization, vaccination and antimicrobial therapy .
This theory changed the way in which pharmacy and medicine were taught from observation to experimentation through laboratory investigation, the isolation of microbes and the development of treatment strategies based on evidence.
Throughout its evolution, a great deal of the history of pharmaceutical microbiology has been marked by significant discoveries that have revolutionised medicine and the pharmaceutical sciences. Louis Pasteur was a pioneer in the development of microbiology as a science. He disproved the theory of spontaneous generation in his experiments and showed that microorganisms are in the environment and cause fermentation and spoilage .
Pasteur was a major contributor to medicine and pharmacy: Invented the pasteurisation process, in which harmful microorganisms are eliminated in food and beverages by controlled heating. Brought in the use of sterilisations and aseptic methods , which were vital in hospitals, laboratories and the pharmaceutical industry. Proved that weakened microorganisms may elicit immunity , and subsequently , vaccines were developed.
Successfully created vaccines for anthrax and rabies, demonstrating the possibility of preventing microbial diseases with vaccines. Pasteur's research proved the significance of the control of microbial contamination in medical and pharmaceutical practices. Robert Koch and Koch's Postulates .
Robert Koch further supported the germ theory by developing scientific criteria to distinguish microorganisms that cause disease. These criteria came to be called Koch's Postulates and were used to establish a connection between a specific microorganism and a specific disease . Koch's postulates include: 1.
Every incidence of the disease should have the presence of the microorganism. 2. It must be grown in pure culture and isolated. 3. When the cultured organism is inoculated into a normal host , it should induce disease. 4.
Microorganism should be re-isolated from the experimentally infected host. These concepts led Koch to the discovery of the causative organisms of three diseases: tuberculosis (Mycobacterium tuberculosis), cholera (Vibrio cholerae), and anthrax (Bacillus anthracis). His findings facilitated accurate diagnosis, were important for the isolation of microorganisms, and proved to be important for developing appropriate treatment strategies , which significantly improved medical microbiology and control of infectious diseases.
The discovery of antibiotics was one of the greatest advances in microbiology and medicine. Antibiotics are chemicals that are produced by microorganisms that inhibit or kill other microorganisms. Penicillin was discovered by Alexander Fleming in 1928, when he noticed the mould Penicillium notatum inhibiting the growth of bacteria.
Fleming noticed that bacteria did not grow near the mould and discovered the first true antibiotic. The discovery of penicillin and milestones of antibiotic development are illustrated in Figure 1.2.
The discovery of penicillin revolutionised medicine because it:
The microorganism is not only used for antibiotic production, but also for modern biotechnology production. In modern times, microbes are used to make therapeutic proteins, vaccines, enzymes and hormones through recombinant DNA (Deoxyribonucleic acid) technology. Recombinant DNA technology is the transfer of a desirable gene into a microbial host such as Escherichia coli or yeast cells.
These GM microbes are used to create factories for the production of medically useful products in significant amounts. The first step is to isolate the gene of interest, for example, insulin or growth hormone, from humans. This gene is placed in plasmid vectors, which are small circular molecules of DNA, to produce a recombinant DNA molecule.
These vectors are then introduced into microbial cells, in a process called transformation. The host cells are then subjected to large-scale microbial fermentation, in which the human protein is expressed in large amounts by the rapidly proliferating cells. The last step is the careful purification of the therapeutic product to make sure that the medicine is exactly like human proteins and doesn't carry the allergic dangers of earlier animal-based therapies.
The production of human insulin by microbes is one of the most significant advances of recombinant technology. Insulin used to be extracted from the pancreas of pigs and cattle, but this sometimes led to allergic reactions and immune reactions. The human insulin gene is transferred to Escherichia coli or yeast, and the microorganisms produce insulin that is the same as natural human insulin using recombinant DNA technology.
Human growth hormone, interferons, clotting factors, monoclonal antibodies and therapeutic enzymes are also made using recombinant microbes. Vaccines and Immunisation Microorganisms are also an important part of vaccine development. Vaccines train the immune system to detect and neutralise disease-causing organisms and to create an immune memory.
Conventional vaccines consisted of attenuated live microbes, killed microbes or toxoids. These vaccines worked well to control diseases like smallpox, polio, diphtheria and measles. Genetic engineering has improved the safety and efficacy of recombinant vaccines.
One of the key examples is the Hepatitis B vaccine, which is made by recombinant DNA technology. A harmless viral surface protein is made in the yeast cells instead of the entire virus, stimulating immunity without causing disease. In addition, modern microbial biotechnology has helped to develop DNA vaccines, mRNA vaccines, and vector-based vaccines, which have enhanced vaccine safety, efficacy and rapid production of vaccines, particularly during global epidemics.
The various processes of recombinant DNA technology for therapeutic protein production are illustrated in Figure 1.3.
Microorganisms are classified into two groups based on their cellular organisation and complexity: In the field of pharmaceutical microbiology, three groups are of particular importance – bacteria, fungi and viruses. The most extensively studied are bacteria, which are important in disease, production of antibiotics, control of contamination and biotechnology.
Bacteria are tiny, single-celled and classified as prokaryotes. Unlike eukaryotic cells, bacterial cells do not have a true membrane-bound nucleus and other membrane-bound organelles. They have a single circular chromosome in the nucleoid region of the cell.
As bacteria multiply by binary fission, they are of interest in infectious diseases and industrial microbiology. Bacteria constitute a very important group in pharmacy because they are pathogenic and cause infectious diseases, they can be used to produce antibiotics and enzymes, they may be contaminants in the pharmaceutical production process, as well as useful organisms in biotechnology and fermentation. General Structure of Bacterial Cells A bacterial cell has multiple components that help it to survive, cause disease and reproduce.
The cell wall is a hard structure outside the plasma membrane that determines cell shape and prevents the cell from bursting open, mainly consisting of peptidoglycan. Transport of nutrients and waste products is controlled by the plasma membrane, which also houses enzymes needed for respiration. The cytoplasm consists of ribosomes, enzymes, nutrients and the bacterial chromosome.
The flagella are whip-like structures that provide motility to the bacterial cells, which facilitate their movement through chemotaxis. Pili are short hairlike extensions used in attachment to host tissues, biofilm and genetic exchange through conjugation. Additionally, some bacteria have an outer gelatinous coat called a capsule that protects them from being dried out, ingested by immune cells and from toxic chemicals, and makes capsulated bacteria, like Streptococcus pneumoniae and Klebsiella pneumoniae, more virulent .
The structure of a bacterial cell is illustrated in
4.
Shapes of Bacteria Bacteria have definite shapes that help to identify them. Cocci are round or oval bacteria which may be found in pairs (diplococci), chains (streptococci) or in clusters like bunches of grapes (staphylococci). A few examples are Staphylococcus aureus and Streptococcus pyogenes.
Cylindrical rod-shaped bacteria are bacilli, e.g. Bacilli bacteria (Bacillus subtilis and Escherichia coli), which can form resistant spores. Comma-shaped curved rod-shaped bacteria, for example, Vibrio cholerae.
There are other forms, such as spirilla (rigid spiral-shaped) and spirochetes (flexible spiral bacteria) like Treponema pallidum. Gram Staining Hans Christian Gram developed the Gram stain, which is an important diagnostic tool and is usually the initial step in the lab identification of bacterial contamination. This staining technique is based on the differential staining of bacteria, which is based on the chemical and physical properties of the cell walls of the bacteria.
Gram-positive bacteria have a thick peptidoglycan layer (15-80 nanometres), which retains the primary dye complex, which can't be washed away during decolourisation. Gram-negative bacteria have a very thin peptidoglycan layer (about nanometres) with an exterior membrane with lipopolysaccharides (LPS), which removes the main dye during decolouration. The structural differentiation of gram-positive and gram-negative bacterial cell walls are displayed in Figure 1.5.
walls
Fungi are eukaryotic microorganisms with a true nucleus and membrane-bound organelles. They are of great importance in the pharmaceutical industry because they can be used to make therapeutic proteins, organic acids, vitamins, enzymes and antibiotics. Fungi fall into two main categories that are of great importance: yeasts and moulds.
Yeasts are unicellular fungi that reproduce primarily by budding or fission. Saccharomyces cerevisiae is widely employed in fermentation, enzyme and vitamin production, recombinant DNA technology to produce therapeutic proteins and vaccines and as a research tool in biotechnology. A mould is a multicellular filamentous fungus with thread-like structures called hyphae, which grow together to form a mycelium.
Some significant examples are Penicillium chrysogenum (Penicillin production), Aspergillus niger (Citric acid and enzyme production) and Cephalosporium acremonium (Cephalosporin antibiotics). Moulds are also significant issues in the pharmaceutical industry regarding raw materials, equipment and finished products contamination by airborne fungal spores, requiring the careful control of air conditions and environmental monitoring.
Pharmacy is concerned with microorganisms that can be broadly divided into prokaryotes and eukaryotes on the basis of their cellular structure and complexity. There are significant differences between these two groups in cell wall composition, presence of organelles, nuclear organization, reproduction and size (Table 1.1). The prokaryotic microorganisms are very simple in structure and have no nucleus.
They multiply rapidly and have a wide range of metabolic activities, which makes them useful in the production of antibiotics, preparation of vaccines, use in recombinant DNA technology and fermentation processes. Many bacteria, however, are pathogenic and cause infectious diseases and contamination of pharmaceutical products; they are also useful for industry. Microorganisms have eukaryotic cells that are structurally more complex, containing compartmentalised organelles, and are also pathogenic and can cause opportunistic infections especially in immunocompromised patients.
Feature Prokaryotes (Bacteria) Eukaryotes (Fungi, Protozoa) Size Usually 0.5–3 µm Generally > 5 µm Nucleus No true membrane-bound nucleus; genetic material lies in the nucleoid region True membrane-bound nucleus present Organelles Membrane-bound organelles absent Organelles such as mitochondria, the Golgi apparatus, and the endoplasmic reticulum are present. Cell Wall Contains peptidoglycan Contains chitin in fungi; absent in protozoa Cellular Complexity Simple cellular organisation More complex cellular organisation Ribosomes 70S ribosomes 80S ribosomes Reproduction Mainly by binary fission Sexual and asexual reproduction Examples Escherichia coli, Bacillus subtilis Saccharomyces, Aspergillus, Amoeba
Viruses are acellular, nonliving infectious particles that can multiply only within living host cells; hence they are called obligate intracellular parasites. They are composed of nucleic acid (DNA or RNA) that is covered by a protein envelope known as a capsid; some have an outer lipid envelope. Viruses are unable to grow on artificial culture media as bacteria and fungi do, and do not have their own metabolic machinery.
Classification of Viruses Viruses are commonly classified as shown in Table 1.2.
Basis of Classification Types Genetic Material DNA viruses, RNA viruses Host Specificity Animal viruses, Plant viruses, Bacterial viruses (Bacteriophages) Structure Enveloped viruses, Non-enveloped viruses Capsid Shape Helical, Icosahedral, Complex Diseases like influenza, rabies, hepatitis and COVID-19 are caused by animal viruses that infect humans and animals. Plant viruses attack plants and decrease crop production, for example the Tobacco Mosaic Virus (TMV). Bacteriophages (phages) are viruses that infect and destroy bacteria; enter the bacteria, inject their genetic material, multiply and then lyse the host cells.
Viruses have many applications in pharmaceutical and biomedical sciences. They are applied in vaccine production (live attenuated and inactivated vaccines), gene therapy (modified viruses used as vectors for therapeutic genes), oncolytic therapy (engineered viruses used for selectively destroying cancer cells) and bacteriophage therapy (phages are being explored as a substitute for antibiotics in the treatment of multidrug resistant bacteria). With the emergence of antibiotic-resistant bacteria like MRSA and Pseudomonas aeruginosa, there is a renewed interest in phage therapy.
Bacteriophages target specific pathogenic bacteria, leaving normal human cells and 'friendly' bacteria alone. Its benefits are high specificity, effectiveness against antibiotic-resistant strains, penetration of bacterial biofilm, and self-replication at the bacterial infection site. The limitations are: narrow host range, the potential for bacterial resistance to phages and regulatory and standardization problems.
The morphological and structural comparison of a bacterium, a fungal cell, and a virus is illustrated in Figure 1.6
virus
Cultivation and isolation of microorganisms is one of the basic techniques of microbiology and pharmaceutical sciences. For the study, identification, and use of microbes in industry and medicine, microbes should be cultured under controlled laboratory conditions using appropriate culture media. The growth of microorganisms depends on their cultivation , which provides the environmental and nutritional requirements for their growth, and pure culture of specific microorganisms from mixed populations is obtained by the process of isolation.
For the growth, metabolism and reproduction of microorganisms, they need various nutrients. Macro-elements are present in relatively large amounts in the media, such as carbon (which is the principle component of cellular material, and is obtained from glucose, lactose, or carbon dioxide); nitrogen (which is needed for amino acids and proteins, and is supplied in the form of ammonium salts, nitrates, or peptones); phosphorus (which is a major component of nucleic acids and ATP, and is provided as phosphates or phosphates combined with ammonium ions); and sulfur (which is needed for sulfur-containing amino acids and coenzymes, and is supplied as sulfurates or sulphonates). Trace elements like zinc, copper, manganese, iron, cobalt and molybdenum are required in extremely low concentrations, but are critical as cofactors of enzyme reactions.
Some of the microorganisms also need growth factors (vitamins, amino acids, purines and pyrimidines) which they cannot produce.
A nutrient preparation used to grow, isolate and identify microorganisms. Culture media can be divided into different types according to their components and use. Defined (synthetic) media have precisely known chemical components with exact chemical proportions and are utilised for physiological and metabolic studies and for optimisation of fermentation in industry.
Selective Media are designed to allow the growth of wanted microorganisms and inhibit the unwanted microorganisms, e.g., MacConkey Agar has bile salts and crystal violet, which inhibit the growth of Gram-positive bacteria but not the Gram-negative bacteria. Differential media can be used to differentiate microorganisms in terms of biochemical or metabolic properties, for example blood agar can be used to distinguish between bacteria that produce different types of hemolysis (alpha, beta, or gamma). Enriched media are made by adding blood, serum or yeast extract to promote the growth of fastidious microorganisms like Streptococcus spp., Neisseria spp., and Haemophilus spp.
Microbial isolation techniques are very important procedures that are employed to isolate and obtain a pure culture of microorganisms from a mixed microbial population. Pure culture is a culture in which only a single type of microorganism is present. Pure culture is required for accurate identification, biochemical characterisation, sensitivity testing against antibiotics, industrial fermentation and pharmaceutical research.
The concept of microbial isolation is that microbial cells can be diluted or physically separated so that each cell grows individually and develops into a separate colony on solid culture media. Streak Plate Method The streak plate method is the most commonly used method for obtaining isolated colonies and pure cultures. The microbial cells are diluted further onto the surface of the agar by repeated streaking on the surface of the agar using the sterile inoculating loop.
As the loop is moved across the surface, the number of microorganisms gradually decreases, until individual microbial cells are seen, which grow into isolated colonies. Simple and economical, this method can serve to obtain pure cultures, but it cannot be used for accurate microbial counting and technique and experience are needed. The streak plate technique for the isolation of individual bacterial colonies are represented in Figure 1.7.
Spread Plate Method Spread plate method: It is a quantitative isolation technique of solidified agar plate media in which a known volume (typically 0.1 mL) of microbial suspension is evenly spread using a sterile glass spreader. Each cell divides into individual colonies, and the number of colonies is proportional to the number of microorganisms in the sample. This method can be used for aerobic microorganisms and yields evenly distributed colonies for enumeration.
Pour Plate Method Diluted samples of microorganisms are added to the molten agar (that is, cooled to about 45°C but not yet solidified) in the pour plate method. The microorganisms are spread throughout the medium and grow into colonies on the surface and in the agar. Useful for both aerobic and facultative anaerobic microorganisms, this technique could allow larger volumes of samples to be processed, though it may cause damage to heat-sensitive microorganisms if the molten agar is used.
These are compared in a table (Table 1.3).
Feature Streak Plate Spread Plate Pour Plate Main Purpose Isolation of pure cultures Enumeration and isolation Enumeration and isolation Sample Placement Surface streaking Spread on agar surface Mixed with molten agar Colony Location Surface only Surface only Surface and within agar Quantitative Analysis Limited Good Good Feature Streak Plate Spread Plate Pour Plate Suitable for Pure Culture Isolation Excellent Moderate Moderate Heat Exposure None None Present Common Use Pure culture preparation Viable count determination Viable count determination
The quantitative assessment of the quantity of microorganisms in a sample is called microbial enumeration. It is one of the most critical procedures in pharmaceutical microbiology that can serve to assess the microbiologic quality, safety and stability of pharmaceutical products, raw materials, water systems and manufacturing areas. Viable Counting (Colony Forming Unit – CFU) Only living microorganisms capable of reproducing and visible colonies on solid culture media are viable in the context of counting.
Colonies are presumed to be derived from a single viable cell or group of identical cells, which is expressed as a Colony Forming Unit (CFU) per mL or g of culture for liquid or solid culture, respectively. In the membrane filtration method, which is regarded as the gold standard for testing pharmaceutical water and injectable products, the sample is passed through a sterile membrane filter (pores 0.22-0.45 µm) which retains microorganisms, but allows the liquid to pass through, the membrane is then cultured and the number of colonies counted. The pour plate and spread plate methods may also be used for viable counting, as described previously .
The serial dilution process to calculate CFU/mL in a pharmaceutical product is illustrated in Figure 1.8.
Most Probable Number (MPN) Method The Most Probable Number (MPN) method is a statistical estimation procedure to determine the concentration of viable microorganisms in liquid sample that is difficult to filter or contains low microbial count. This is done through serial dilution and inoculation of liquid broth media, following which the tubes with microbial growth (turbidity, gas production or colour change) are marked positive and the pattern compared to standard probability tables to estimate the microbial population. Rapid and Modern Methods Typically, any microbial method of culture takes a week or more to get a visible culture.
If less time is needed for testing, pharmaceutical industries increasingly rely on rapid microbiological techniques. ATP bioluminescence quantifies the adenosine triphosphate (ATP) with the enzyme luciferase and the amount of light produced is proportional to ATP levels and can be measured within minutes by luminometer, which indicates the presence of microbial contamination. MALDI-TOF (Matrix-Assisted Laser Desorption Ionization–Time of Flight) Mass Spectrometry is a fast method used to identify microorganisms in just a few minutes, by using a laser to ionize microbial proteins, then comparing the resultant unique protein spectrum with a reference database.
In the pharmaceutical industry, microorganisms occupy an interesting position as biological plants for the production of valuable pharmaceuticals and as being part of the contaminant fraction, which must be eliminated from the final product. Production of Bioactive Substances Microorganisms have been widely used to make numerous pharmaceutical products using chemical transformations and fermentation. Antibiotics are the most important ones; penicillin, being produced from Penicillium notatum in 1928, was a revolutionary breakthrough, and 80-90% of the present-day antibiotics are obtained from Actinomycetes.
Microbes also play an important role as agents for the large-scale production of vitamins (Vitamin B12), enzymes (streptokinase and urokinase), organic acids (citric acid) and amino acids. The recombinant DNA technology allows large-scale production of proteins like insulin and growth hormones in microorganisms like Escherichia coli . Key Antibiotics and Their Sources Penicillin is the first antibiotic that was discovered, and it is a beta-lactam antibiotic.
The principal mechanism of action is interference with the synthesis of the bacterial cell wall by binding to transpeptidases (beta-lactamases) and thereby blocking the cross-linking of peptidoglycan subunits, which results in cell lysis and death. Selman Abraham Waksal discovered Streptomycin, an aminoglycoside antibiotic derived from Actinomycetes, which is an important antimycobacterial drug for treating tuberculosis due to Mycobacterium tuberculosis . Cephalosporins are a class of beta-lactam antibiotics that are also produced by certain fungi and make use of them as broad-spectrum chemotherapeutic agents, especially beneficial in the treatment of patient who have become resistant to penicillin.
Metabolic products produced by microorganisms which have inhibitory effect on other microorganisms even at low concentrations are called antibiotics. It is called antibiosis and is due to the secretion of specific chemical substances by a microbe which hinders the growth of another microbe. Identification and large-scale manufacture of these "wonder drugs" by the science of industrial microbiology and fermentation has been one of the most revolutionary achievements in medical history.
Discovery and Source: Penicillin is the first antibiotic that was ever discovered, it was discovered by chance in by Sir Alexander Fleming. Colonies of Staphylococci were breaking up around a mold of Penicillium notatum contaminating a culture plate. Bacteria of the genus Penicillium were found to be the source of the active substance, and the Penicillium chrysogenum species and other Penicillium species are now commonly used for pharmaceutical production, in the kingdom of Fungi.
Production and Mechanism: Modern penicillin is produced by using large scale fermentation technology. This process is known as mass culture of fungi, the production of the bioactive substance is maximized from the fungi in a nutrient rich medium under strict control of parameters. Penicillin is a member of the beta-lactam group of antibiotics.
It acts mainly by disrupting the synthesis of cell wall of bacteria. It works by binding to transpeptidases, an inhibition of cross linking the peptidoglycan subunits. Once the cell wall is damaged, the cell is unable to replicate by binary fission and the cell eventually bursts open and dies.
Uses: Treatment of infections due to gram positive bacteria ( Staphylococci and Streptococci ). Use for systemic infections, which is often seen in balancing with possible allergic reactions in the patients. The molecular mechanism of penicillin inhibition of peptidoglycan cross-linking in the bacterial cell wall is displayed in Figure 1.9.
in the bacterial cell wall 1.6.2. Streptomycin Discovery and Source: Streptomycin was discovered by Waksman and his colleagues. It comes from Actinomycetes which are prokaryotes found in soil and that are a link between bacteria and fungi.
This group holds great pharmaceutical significance because the Actinomycetes are the source of 80-90% of the antibiotics, which are in use in therapeutics. Production: Streptomycin is produced, as with penicillin, by industrial-scale fermentation of specially selected strains of Streptomyces. The production is optimized to yield the microbes with high concentrations of the drug, due to the nature of the metabolic reactions.
It is a type of antibiotic called an aminoglycoside. Uses: Streptomycin is an important antitubercular drug, which is mainly used for the treatment of tuberculosis caused by Mycobacterium tuberculosis . It has also been used in the treatment of other infections, in which it is needed for special antimicrobial activity.
The microscopic morphology of actinomycetes hyphae and structural adaptation is illustrated in Figure 1.10.
adaptation 1.6.3. Cephalosporins Discovery and Source: Cephalosporins were discovered as one of the great achievements in drug discovery along with penicillin and streptomycin. They are made by certain types of fungi and belong to a class of antibiotics called beta-lactam antibiotics, which have a similar structure to penicillins.
Cephalosporin Production: It is a pivotal application in the pharmaceutical industry, involves recombinant DNA technology, and advanced fermentation techniques to produce semi-synthetic cephalosporins. This enables optimization of the antibiotic, to make it safer, more stable and effective against resistant strains. Uses: Broad-spectrum chemotherapeutic agents, Cephalosporins, are used for different types of bacterial infections.
They are of special value in patients who have developed a resistance to penicillin or need an agent that has a different pharmacological profile. Quality Control and Safety An important aspect of pharmaceutical microbiology is ensuring that pharmaceutical products are free from harmful microorganisms and microbial contaminants. Microbial spoilage can reduce the efficacy of active pharmaceutical ingredients, alter the pH and stability of formulations, and lead to serious infections in patients.
Therefore, rigorous microbiological monitoring and quality assurance programs are essential during the manufacturing, storage and distribution of pharmaceutical products. Sterility testing is particularly important for sterile dosage forms such as injections, ophthalmic preparations and intravenous fluids to ensure the complete absence of viable microorganisms. In parenteral products, the presence of endotoxins produced by Gram-negative bacteria can cause fever, inflammation and septic shock even after the bacteria are destroyed.
Hence, the Bacterial Endotoxins Test (BET) is routinely performed to ensure the safety of injectable preparations. In addition, pharmaceutical industries follow strict aseptic techniques, environmental monitoring procedures and Good Manufacturing Practices (GMP) to maintain product quality, safety and efficacy. Industrial fermentation process for antibiotic production The industrial fermentation process for antibiotic production involves a series of carefully controlled procedures to obtain high yields of pure and effective antibiotics.
Initially, a high-yielding and non-pathogenic microbial strain is selected and improved through mutation, genetic engineering or classical strain improvement techniques to enhance productivity and stability. The selected microorganism is then inoculated into a sterile seed medium and incubated under aseptic conditions to obtain an active and healthy inoculum for large-scale production. The prepared inoculum is transferred into large production fermenters containing sterilized production media.
During fermentation, optimal conditions such as temperature, pH, aeration, agitation and foam control are carefully maintained to maximize antibiotic production. Fermentation may continue for several hours to several days depending on the type of microorganism and antibiotic produced. After completion of fermentation, microbial cells and solid debris are separated from the fermentation broth using filtration, centrifugation or microfiltration techniques.
The antibiotic is then recovered from the clarified broth or biomass using suitable extraction methods such as solvent extraction, adsorption or ion-exchange processes. The extracted antibiotic solution is subsequently concentrated and purified using methods including precipitation, crystallization, chromatography, membrane filtration and activated carbon treatment to remove impurities and improve potency. The purified antibiotic solution is further concentrated and converted into a stable solid form through spray drying, freeze drying or vacuum drying techniques.
Depending on the intended pharmaceutical application, the purified antibiotic may then be formulated into dosage forms such as tablets, capsules, powders, injectables or ointments using suitable excipients. Finally, the finished product undergoes rigorous quality control testing to evaluate purity, potency, sterility, stability, moisture content and identity according to standard specifications. The antibiotic product is then packaged under aseptic conditions and stored appropriately to maintain its safety, efficacy and stability.
Throughout the entire process, strict aseptic techniques, continuous process monitoring, quality assurance measures and compliance with Good Manufacturing Practices (GMP) are maintained to ensure high-quality antibiotic production. Antibiotic Resistance Although antibiotics have helped save lives, many have developed a resistance for a number of different antibiotics, which are called super bacteria. Resistance to almost all antibiotics is now present in some pathogens and the conjugative transfer of antibiotic resistant plasmids is a serious challenge.
This requires continued research on pharmaceuticals for the discovery of new antimicrobials of microbial origin and genetic engineering for novel antimicrobial approaches.
Pharmaceutical microbiology is a discipline of dual significance as microorganisms are essential in the manufacture of life-saving drugs and as a significant risk factor as a contaminant. The chapter has given an overview of the important classes of microorganisms of pharmaceutical importance, such as bacteria, fungi and viruses, explaining their structural features, pharmaceutical importance and their role in disease and drug production. Modern pharmaceutical science has been defined by three turning points in history: the germ theory, the discovery of antibiotics and the biopharmaceutical revolution.
In the pharmaceutical sector, techniques of microbial cultivation, isolation, and enumeration play a vital role in maintaining product quality, safety, and regulatory compliance. These concepts are fundamental to students and practitioners in the pharmaceutical sciences, biotechnology, and health care, and they are the scientific foundation for the safe and ethical applications of microorganisms in the treatment of disease and the continued fight against antimicrobial resistance.
1 van Doorne, H., Roesti, D., & Staerk, A. (2015). Microbiology.
In Practical pharmaceutics (pp. 383–403). Springer. https://doi.org/10.1007/978-3-319-15814-3_19 2 Ratajczak, M., Kubicka, M. M., Kamińska, D., Sawicka, P., & Długaszewska, J.
(2015). Microbiological quality of non-sterile pharmaceutical products. Saudi Pharmaceutical Journal, 23(3), 303–307. https://doi.org/10.1016/j.jsps.2014.11.015 3 Singer, D.
C., Gross, D. D., & Cundell, A. M.
(2025). The role of microbiologists in drug product development. PDA Journal of Pharmaceutical Science and Technology, 79(4), 401–407. https://doi.org/10.5731/pdajpst.2025-000010.1 4 Vu, N., Lou, J.
R., & Kupiec, T. C. (2014).
Quality control analytical methods: Microbial limit tests for nonsterile pharmaceuticals, Part 1. International Journal of Pharmaceutical Compounding, 18(3), 213–221. 5 Jimenez, L. (2007).
Microbial diversity in pharmaceutical product recalls and environments. PDA Journal of Pharmaceutical Science and Technology, 61(5), 383–399. 6 Burke, C. J., Hsu, T.
A., & Volkin, D. B. (1999).
Formulation, stability, and delivery of live attenuated vaccines for human use. Critical Reviews in Therapeutic Drug Carrier Systems, 16(1), 1–83. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v16.i1 7 Pasteur, Joubert, & Chamberland. (1879).
On the germ theory. Edinburgh Medical Journal, 25(3), 265–268. 8 Croce, P. (1996).
The four postulates of Robert Koch. Rivista di Biologia, 89(2), 275–278. 9 Evans, D. W.
(2022). How to gain evidence for causation in disease and therapeutic intervention: From Koch’s postulates to counter-counterfactuals. Medical Health Care and Philosophy, 25(3), 509–521. https://doi.org/10.1007/s11019-022-10096-x 10 Fleming, A.
(1929). On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzæ. British Journal of Experimental Pathology, 10(3), 226–236. https://pmc.ncbi.nlm.nih.gov/articles/PMC2048009/ 11.
Aminov, R. I. (2010).
A brief history of the antibiotic era: Lessons learned and challenges for the future. Frontiers in Microbiology, 1, 134. https://doi.org/10.3389/fmicb.2010.00134 12. BĂ©rdy, J.
(2005). Bioactive microbial metabolites. Journal of Antibiotics, 58(1), 1–26. https://doi.org/10.1038/ja.2005.1 13.
Hancock, R. E. W., & Sahl, H.-G.
(2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology, 24(12), 1551–1557. https://doi.org/10.1038/nbt1267 14.
Walsh, G. (2018). Biopharmaceutical benchmarks 2018.
Nature Biotechnology, 36(12), 1136–1145. https://doi.org/10.1038/nbt.4305 15. Johnson, I. S.
(1983). Human insulin from recombinant DNA technology. Science, 219(4585), 632–637. https://doi.org/10.1126/science.6337396 16.
Goeddel, D. V., Kleid, D. G., Bolivar, F., Heyneker, H.
L., Yansura, D. G., Crea, R., Hirose, T., Kraszewski, A., Itakura, K., & Riggs, A. D.
(1979). Expression in Escherichia coli of chemically synthesized genes for human insulin. Proceedings of the National Academy of Sciences, 76(1), 106–110. https://doi.org/10.1073/pnas.76.1.106 17.
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D.
(2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243 18. Madigan, M.
T., Bender, K. S., Buckley, D. H., Sattley, W.
M., & Stahl, D. A. (2021).
Brock biology of microorganisms (16th ed.). Pearson. 19. Silhavy, T.
J., Kahne, D., & Walker, S. (2010). The bacterial cell envelope.
Cold Spring Harbor Perspectives in Biology, 2(5), a000414. https://doi.org/10.1101/cshperspect.a000414 20. Kline, K. A., Fälker, S., Dahlberg, S., Normark, S., & Henriques-Normark, B.
(2009). Bacterial adhesins in host–microbe interactions. Cell Host & Microbe, 5(6), 580–592. https://doi.org/10.1016/j.chom.2009.05.011 21.
Whitfield, C. (2006). Biosynthesis and assembly of capsular polysaccharides in Escherichia coli.
Annual Review of Biochemistry, 75, 39–68. https://doi.org/10.1146/annurev.biochem.75.103004.142545 22. Hugo, W. B., & Russell, A.
D. (2004). Pharmaceutical microbiology (7th ed.).
Blackwell Science. 23. Madigan, M. T., Martinko, J.
M., Bender, K. S., Buckley, D. H., & Stahl, D.
A. (2015). Brock biology of microorganisms (14th ed.).
Pearson Education. 24. Moyes, R. B., Reynolds, J., & Breakwell, D.
P. (2009). Differential staining of bacteria: Gram stain.
Current Protocols in Microbiology, Appendix 3, Appendix 3C. https://doi.org/10.1002/9780471729259.mca03cs15 25. Riquelme, M., Munro, C., & Gow, N. (2020).
The fungal cell wall: Biology, biosynthesis and biotechnology. Cell Surface, 6, 100037. https://doi.org/10.1016/j.tcsw.2020.100037 26. Racioppo, A., & Guerrieri, A.
(2025). Fungi. In The microbiological quality of food (2nd ed., pp. 175–195).
Woodhead Publishing. https://doi.org/10.1016/B978-0-323-91160-3.00009-X 27. Flint, S. J., Enquist, L.
W., Racaniello, V. R., & Skalka, A. M.
(2020). Principles of virology (5th ed.). ASM Press. 28.
Lefkowitz, E. J., Dempsey, D. M., Hendrickson, R.
C., Orton, R. J., Siddell, S. G., & Smith, D.
B. (2018). Virus taxonomy: The database of the ICTV.
Nucleic Acids Research, 46(D1), D708–D717. https://doi.org/10.1093/nar/gkx932 29. Summers, W. C.
(2009). Virus infection. In Encyclopedia of microbiology (pp. 546–552). https://doi.org/10.1016/B978-012373944-5.00323-0 30.
Fortaleza, J. A. G., Ong, C.
J. N., & De Jesus, R. (2024).
Efficacy and clinical potential of phage therapy in treating MRSA infections: A review. European Journal of Microbiology & Immunology, 14(1), 13–25. https://doi.org/10.1556/1886.2023.00064 31. SantamarĂa-Corral, G., Senhaji-Kacha, A., Broncano-Lavado, A., Esteban, J., & GarcĂa-Quintanilla, M.
(2023). Bacteriophage-antibiotic combination therapy against Pseudomonas aeruginosa. Antibiotics, 12(7), 1089. https://doi.org/10.3390/antibiotics12071089 32.
Subramanian, A. (2024). Emerging roles of bacteriophage-based therapeutics in combating antibiotic resistance.
Frontiers in Microbiology, 15, 1384164. https://doi.org/10.3389/fmicb.2024.1384164 33. Bonnet, M., Lagier, J. C., Raoult, D., & Khelaifia, S.
(2020). Bacterial culture through selective and non-selective conditions. New Microbes and New Infections, 34, 100622. https://doi.org/10.1016/j.nmni.2019.100622 34.
Sanders, E. R. (2012).
Aseptic laboratory techniques: Plating methods. Journal of Visualized Experiments, (63), e3064. https://doi.org/10.3791/3064 35. Jung, B.
(2020). MacConkey medium. In StatPearls.
StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557394/ 36. Vandepitte, J., Verhaegen, J., Engbaek, K., Rohner, P., Piot, P., & Heuck, C. C.
(2003). Basic laboratory procedures in clinical bacteriology (2nd ed.). World Health Organization. 37.
Dahal, P., & Aryal, S. (2025). Streak plate method: Principle, types & step-by-step guide.
Microbe Notes. https://microbenotes.com/streak-plate-method-principle-methods-significance-limitations/ 38. Dahal, P. (2022).
Spread plate method—Definition, principle, procedure, uses. Microbe Notes. https://microbenotes.com/spread-plate-technique/ 39. Dahal, P.
(2022). Pour plate method—Definition, principle, procedure, uses. Microbe Notes. https://microbenotes.com/pour-plate-technique-procedure-significance-advantages-limitations/ 40.
Terrones-Fernández, I., Casino, P., LĂłpez, A., PeirĂł, S., RĂos, S., Nardi-Ricart, A., GarcĂa-Montoya, E., Asensio, D., MarquĂ©s, A. M., Castilla, R., Gámez-Montero, P. J., & PiquĂ©, N.
(2023). Improvement of the pour plate method by separate sterilization of agar and other medium components and reduction of the agar concentration. Microbiology Spectrum, 11 (1), e0316122. https://doi.org/10.1128/spectrum.03161-22 41.
Jimenez, L. (2026). Microbial landscape of pharmaceutical failures: A 21-year review of FDA enforcement reports.
BioTech, 15 (1), 8. https://doi.org/10.3390/biotech15010008 42. Meyer, C. T., Lynch, G.
K., Stamo, D. F., Miller, E. J., Chatterjee, A., & Kralj, J.
M. (2023). A high-throughput and low-waste viability assay for microbes.
Nature Microbiology, (12), 2304–2314. https://doi.org/10.1038/s41564-023-01513-9 43. Eldemerdash, A., Ewaisha, R., Alseqely, M., & Shehat, M. G.
(2025). Optimizing neutralization strategies for microbial testing of non-sterile pharmaceutical finished products with challenging method suitability. BMC Microbiology, 25 , 748. https://doi.org/10.1186/s12866-025-04456-9 44.
Moussa, M., Marcelino, I., Richard, V., Guerlotté, J., & Talarmin, A. (2020). An optimized most probable number (MPN) method to assess the number of thermophilic free-living amoebae in water samples.
Pathogens, 9 (5), 409. https://doi.org/10.3390/pathogens9050409 45. Kator, H., & Rhodes, M. (2003).
Detection, enumeration and identification of environmental microorganisms of public health significance. In D. Mara & N.
Horan (Eds.), Handbook of water and wastewater microbiology (pp. 113–144). Academic Press. https://doi.org/10.1016/B978-012470100-7/50009-1 46. Liu, S., Zhao, J., Guo, Y., Ma, X., Sun, C., Cai, M., Chi, Y., & Xu, K.
(2023). Application of ATP-based bioluminescence technology in bacterial detection: A review. The Analyst, (15), 3452–3459. https://doi.org/10.1039/d3an00576c 47.
Chen, X. F., Hou, X., Xiao, M., Zhang, L., Cheng, J. W., Zhou, M.
L., Huang, J. J., Zhang, J. J., Xu, Y.
C., & Hsueh, P. R. (2021).
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis for the identification of pathogenic microorganisms: A review. Microorganisms, (7), 1536. https://doi.org/10.3390/microorganisms9071536 48. Torres-Sangiao, E., Leal RodrĂguez, C., & GarcĂa-Riestra, C.
(2021). Application and perspectives of MALDI-TOF mass spectrometry in clinical microbiology laboratories. Microorganisms, (7), 1539. https://doi.org/10.3390/microorganisms9071539 49.
Patnaik, P. R. (2001).
Penicillin fermentation: Mechanisms and models. Critical Reviews in Microbiology, (1), 25–39. https://doi.org/10.1080/20014091096684 50. De Simeis, D., & Serra, S.
(2021). Actinomycetes as a source of bioactive compounds. Antibiotics, 10, 483. https://doi.org/10.3390/antibiotics10050483 51.
Demain, A. L., & Martens, E. (2017).
Production of valuable compounds by molds and yeasts. Journal of Antibiotics, 70, 347–360. https://doi.org/10.1038/ja.2016.121 52. Cairns, T.
C., Nai, C., & Meyer, V. (2018). How a fungus shapes biotechnology.
Fungal Biology and Biotechnology, 5, 13. https://doi.org/10.1186/s40694-018-0054-5 53. Tobin, E. H., Jogu, P., & Koirala, J.
(2025). Methicillin-resistant Staphylococcus aureus. In StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK482221/ 54.
Bhattacharjee, J., & Roy, S. (2026). Current trends in antibiotic production.
Next Sustainability, 7, 100289. https://doi.org/10.1016/j.nxsust.2026.100289 55. Narendrakumar, L., et al. (2023). β- lactam potentiators to re-sensitize resistant pathogens.
Frontiers in Microbiology, 13, 1092556. https://doi.org/10.3389/fmicb.2022.1092556 56. Pham, P. V.
(2018). Medical biotechnology: Techniques and applications. In Omics technologies and bio-engineering (pp. 449–469). https://doi.org/10.1016/B978-0-12-804659-3.00019-1 57.
Sengupta, S., et al. (2013). Multifaceted roles of antibiotics in nature.
Frontiers in Microbiology, 4, 47. https://doi.org/10.3389/fmicb.2013.00047 58. Alam, K., et al. (2022).
Streptomyces: The biofactory of secondary metabolites. Frontiers in Microbiology, 13, 968053. https://doi.org/10.3389/fmicb.2022.968053 59. Khadayat, K., et al.
(2020). Molecular identification and antimicrobial potential of Streptomyces. International Journal of Microbiology, 2020, 8817467. https://doi.org/10.1155/2020/8817467 60.
Hopwood, D. A. (2019).
Highlights of Streptomyces genetics. Heredity, 123(1), 23–32. https://doi.org/10.1038/s41437-019-0196-0 61. Lin, X., & Kück, U.
(2022). Cephalosporins as beta-lactam antibiotics. Applied Microbiology and Biotechnology, 106(24), 8007–8020. https://doi.org/10.1007/s00253-022-12272-8 62.
Bui, T., Patel, P., & Preuss, C. V. (2024).
Cephalosporins. In StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551517/ 63. Bush, K., & Bradford, P.
A. (2016). Beta-lactams and beta-lactamase inhibitors.
Cold Spring Harbor Perspectives in Medicine, 6(8), a025247. https://doi.org/10.1101/cshperspect.a025247 64. Tyski, S., Burza, M., & Laudy, A. E.
(2025). Microbiological contamination of medicinal products. Pharmaceuticals, 18(7), 946. https://doi.org/10.3390/ph18070946 65.
Coelho, J. M., Bento, C., & Martins, I. (2025).
Microbiological quality and stability of pharmaceutical products in Europe. Preprints, 2025031949. https://doi.org/10.20944/preprints202503.1949.v2 66. Batoni, G., Maisetta, G., Brancatisano, F.
L., Esin, S., & Campa, M. (2011). Antimicrobial peptides against biofilms.
Current Medicinal Chemistry, 18(2), 256–279. https://doi.org/10.2174/092986711794088399 67. Zhgun, A. A.
(2024). Pharmaceutical fermentation: Antibiotic production and processing. Fermentation, 10, 419. https://doi.org/10.3390/fermentation10080419 68.
Fedorenko, V., Genilloud, O., Horbal, L., Marcone, G. L., Marinelli, F., Paitan, Y., & Ron, E. Z.
(2015). Antibacterial discovery and development: From gene to product and back. BioMed Research International, , 591349. https://doi.org/10.1155/2015/591349 69.
Hashim, S. T., Al-Taei, S. R.
K., Saleh, T. H., & Al-Rubaii, B. A.
(2024). Article review: Production and purification of antibiotics from environmental microorganism. Stallion Journal of Multidisciplinary Association Research Studies, 3 (4), 11–24. https://doi.org/10.55544/sjmars.3.4.2 70.
Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023).
Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review. Pharmaceuticals, (11), 1615. https://doi.org/10.3390/ph16111615
This preview stops at Chapter 1. Sign up to unlock full chapters, quizzes, and progress tracking.